Trypanosoma vivax Vivaxin protein (Vivaxin)

Trypanosoma vivax Vivaxin proteins constitute a large family of approximately 124 transmembrane glycoproteins located on the cell surface and flagellar membrane of the T. vivax parasite [1][2]. Unlike the highly variable Variant Surface Glycoproteins (VSGs) that typically enable immune evasion through antigenic variation, Vivaxin proteins are relatively invariant across different parasite strains, making them primary candidates for vaccine development against Animal African Trypanosomiasis (Nagana) [1][5]. These proteins are essential components of the parasite's glycocalyx and are thought to play significant roles in host-parasite interactions and adhesion [1][6]. Experimental studies have shown that vaccination with certain Vivaxin members, specifically IFX (also known as VIVβ1), can induce sterile protection in animal models through antibody-mediated mechanisms involving complement recruitment [5][8]. However, the substantial size of the gene family and evidence that some epitopes may be shielded from host antibodies in vivo present therapeutic challenges for universal vaccine design [1][10]. Overall, Vivaxins represent a critical advance in identifying stable surface targets for controlling trypanosomal infections in livestock [1][9].

Other names

Fam34 gene family proteinTrypanosoma vivax-specific surface proteinVIVβ8IFXInvariant flagellum antigen from T. vivaxVIVβ1

Antibody-mediated neutralization of the parasite and recruitment of the complement system to induce parasite lysis upon binding to invariant surface epitopes [5][10].